Navigation Links
GP targets on heart disease should be simpler and based more on treatment and prevention
Date:9/14/2007

GP performance related payments for tackling heart disease are too complex. They should be simplified and based more on disease treatment and prevention and less on risk factor measurement, experts advise in this weeks BMJ.

General practice in the United Kingdom has the largest healthcare pay for performance programme in the world the quality and outcomes framework (QOF). Practices earn points for the services they provide and these points attract financial resources into the practice.

Professor Bruce Guthrie and colleagues discuss the effectiveness of the system in relation to the management of cardiovascular disease and show how practices can earn many points and extra payments without necessarily reducing its risk.

For example, a practice could receive nine points (each worth about 125) for generating a list of patients with high blood pressure. An extra 30 points would be earned if 90% or more of such patients have a record of risk factors (blood pressure and smoking history) in their notes, and 56 more points would be earned if 70% or more of such patients have a record of blood pressure lowered to below specific target values.

Overall, 15% of payments, worth an estimated 200m across the approximate 11,000 general practices in the UK, arise from measuring cardiovascular risk factors (such as blood pressure and cholesterol) and recording whether they are below specified values.

They reason that its time to incorporate treatment information into quality indicators, since it is the treatment of risk factors that reduces risk, not their measurement.

Meeting current targets for cardiovascular disease does not guarantee good management, they warn. Treatment information would clearly identify opportunities for intervention and improved patient care.

These views are supported by Consultant Cardiologist, David Wald, in an accompanying editorial. He believes that the treatment and prevention of c
'/>"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-020-738-36529
BMJ-British Medical Journal
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Scios Inc. targets drug giants in arthritis war
2. Research Targets treatment for dementia and brain injuries
3. Cancer Treatments Fall Short Of Targets
4. India Targets Eliminating Leprosy
5. Study Would Pave Way for the Development of New Drugs That Targets TB Proteasome
6. Health Targets To Treat Cancer Patients Unlikely To Be Met
7. "Super Drug" Targets Disease-Causing Gene
8. Queensland Government to Meet its Medical Targets
9. No Clear Evidence for Ultra-Low Cholesterol Targets?
10. Health Minister Stresses the Importance of Realistic Health Targets
11. NIDs Targets Immunizations To 22 Million Children In Bangladesh
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 As concerns about ... power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) in gynecological surgeries ... detailing the continued use of uterine morcellation by ... specifically discouraged these procedures. According to The Wall ... cancer risks associated with power morcellators are overblown, ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... new AS365 N3+ Dauphin, the latest version of Airbus ... is based at Miami Valley Hospital in ... medical transport helicopters. , “We have a lot of ... Vice President, Emergency, Trauma, and CareFlight. “We’ve been operating ...
(Date:9/22/2014)... Diego CA (PRWEB) September 22, 2014 ... significantly expand its work to equip women around the ... on poverty. Through the Women Empowered (WE) Initiative ... will now join community-led groups to pool their savings, ... , “Women are the solution to ending poverty in ...
(Date:9/22/2014)... September 22, 2014 The New York ... of Surgery at the Icahn School of Medicine at ... York Group for Plastic Surgery gives residents of New ... a team of world-renowned plastic surgeons performing innovative reconstructive ... Salzberg, MD, who led NYGPS, was named the Director ...
(Date:9/22/2014)... WHO: LiveOps, Inc., the global leader ... , WHAT: The 10th annual Customer Response Summit ... the connected consumer. Constant change in technology and ... and opportunities for customer experience executives. The Summit ... network and learn from fellow attendees, speakers and ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 2Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 3Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2
... YORK, Oct. 8 "Fluoridation of drinking,water is scientifically ... initiative or program," says the Canadian Association of Physicians,for ... CAPE is Canada,s leading voice on environmental health issues., ... fluoridation of public,drinking water in several communities in Alberta, ...
... New interim guidance,that outlines how to become a ... U.S. Department of Health and Human Services., ... Safety Act),authorized the creation of PSOs to improve ... patient safety events. By providing both privilege,and confidentiality, ...
... appears to sustain insulin production in the newly diagnosed. ... have developed a vaccine that may change the way ... diagnosed with type 1 diabetes. , "By a very ... save [a person,s] own insulin secretion, which may be ...
... N.J., Oct. 8 Quest Diagnostics,Incorporated (NYSE: DGX ... services, announced today that its third-quarter,2008 results will be ... and that it will hold its quarterly conference call ... ET on that day., The public may access ...
... The following statement,of Matthew L. Myers was released today ... reports, R.J. Reynolds has announced plans to,test-market three new ... "fresh" and "mellow" flavors and have slick, colorful,packaging similar ... Orbs,these new products also carry the name of RJR,s ...
... HOLE, MA Osamu Shimomura, a senior scientist emeritus ... has been awarded the Nobel Prize in Chemistry for ... the most important tools in contemporary science and medicine ... Shimomura shares the prize, which was announced early today ...
Cached Medicine News:Health News:Physicians' Group Rejects Fluoridation 2Health News:HHS Issues Interim Guidance for Patient Safety Organizations 2Health News:New Vaccine May Help Type 1 Diabetics in Future 2Health News:New Vaccine May Help Type 1 Diabetics in Future 3Health News:Quest Diagnostics to Release Third Quarter 2008 Financial Results 2Health News:R.J. Reynolds' New Smokeless Products Will Appeal to Children and Show Need for FDA Regulation of Tobacco Products 2Health News:MBL scientist Osamu Shimomura wins Nobel Prize for discovery of green fluorescent protein 2Health News:MBL scientist Osamu Shimomura wins Nobel Prize for discovery of green fluorescent protein 3
(Date:9/22/2014)... DIEGO , Sept. 22, 2014  Aethlon ... targeted therapeutic devices to address infectious disease, cancer ... Defense Advanced Research Projects Agency (DARPA) has informed ... option to proceed with year four of a ... Aethlon on September 30, 2011 under DARPA,s Dialysis-Like ...
(Date:9/22/2014)... Inc. (NYSE MKT: CUR) announced that Jonathan D. ... long-term follow up data on the Phase I trial ... of amyotrophic lateral sclerosis (ALS or Lou Gehrig,s ... Symposium on ALS of the Foundation Andre-Delambre, in ... not open to the public, covered data up to ...
(Date:9/22/2014)... CENTER VALLEY, Pa. , Sept. 22, 2014 ... and delivering innovative solutions for medical and surgical ... has reached a deal with Munich ... distributor of Kick ® Navigation. This agreement ... maintain distribution for cross-disciplinary U.S. sales and all ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4
... , , DALLAS , February ... and Central Labs events present Advanced,Biomarker Strategies in Oncology Drug Development. ... from February 4-5, 2010 . This,event is FREE for executives ... This two-day program focuses exclusively on the latest developments in,oncology biomarkers. ...
... RESEARCH TRIANGLE PARK, N.C. , Jan. 29 ... the U.S. Food and Drug Administration has approved ... in patients ages 13 years and older with primary generalized ... XR is approved for partial onset seizures ...
Cached Medicine Technology:MarketsandMarkets Partners With IIR USA for Their Event 'Advanced Biomarker Strategies in Oncology Drug Development' 2MarketsandMarkets Partners With IIR USA for Their Event 'Advanced Biomarker Strategies in Oncology Drug Development' 3FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 2FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 3FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 4FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 5FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 6FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 7
The first book to translate key medical data into clear guidelines capturing the highest treatment standards for heart disease....
DxRxValv contains tables and figures to summarize important clinical data and current professional society recommendations. This handy manual details precise, up-to-date information for diagnosis and...
... Dx/Rx: Coronary Thrombosis ... flowcharts which facilitate transformation ... protocols from static images ... support tools. Details precise, ...
Cardiology Intensive Board Review is geared specifically to candidates taking the Cardiovascular Boards and the Cardiovascular section of the Internal Medicine Boards....
Medicine Products: